Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress

Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress

  • Preliminary findings from Part 1 of the FIREFISH study show that infants with Type 1 SMA are meeting developmental milestones including sitting without support
  • Preliminary data from Part 1 of the SUNFISH study show improvements in motor function in people with Type 2/3 SMA
  • No drug-related safety findings leading to withdrawal in risdiplam trials to date

Roche today announced interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam (RG7916) in SMA. In the FIREFISH study in Type 1 SMA, six out of 14 infants (43%) were able to sit (with or without support), including three (21%) who achieved unassisted stable sitting after eight months of treatment. In addition, four infants (29%) demonstrated rolling to the side; seven (50%) kicking and six (43%) achieved upright head control. These milestones were assessed according to the Hammersmith Infant Neurological Examination (HINE) Module 2 and are key secondary endpoints in the confirmatory part of FIREFISH.

The data were presented at the 23rd International Annual Congress of the World Muscle Society in Mendoza, Argentina. Roche is leading the clinical development of risdiplam, an oral SMN2 splicing modifier, as part of a collaboration with the SMA Foundation and PTC Therapeutics.

“We are highly encouraged by these data showing infants treated with risdiplam surviving and achieving developmental milestones beyond the natural history of this devastating disease,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “SMA therapies that produce a sustained increase in SMN protein in both the CNS and periphery may provide comprehensive benefits to people diagnosed with SMA, and we look forward to sharing additional data on risdiplam as the clinical program progresses.”

Updated analyses of the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND), a scale developed to assess motor function in infants with Type 1 SMA, demonstrated that eight out of 14 infants in FIREFISH (57%) achieved a score of 40 or above at their eight month visit. Typically, an infant with Type 1 SMA does not demonstrate any motor improvement and can decline during this time period. The median CHOP-INTEND scores increased over time (37.5 at 6 months [n=20] compared to 41.5 at eight months [n=14]). The median age at first dose in FIREFISH was 6.7 months and median treatment duration was 9.5 months. Nineteen out of 21 infants enrolled (90%) remain alive with two having discontinued due to the fatal progression of their disease. Three patients are now over 24 months old. No infant has required a tracheostomy or permanent ventilation since study initiation, and no infant has lost the ability to swallow. The most common adverse events were fever (pyrexia; 52.4%), diarrhea (26.8%), upper respiratory tract infections (19%), ear infections (14.3%), pneumonia (14.3%), constipation (14.3%), vomiting (14.3%), cough (14.3%) and upper respiratory tract inflammation (14.3%).

In Part 1 of the SUNFISH study in Type 2 and 3 SMA, SMN protein median increases of greater than 2-fold, as measured in blood, were seen after 12 months. A very broad patient population aged between 2-24 years was included, ranging in functional status from weak non ambulant to strong ambulant, and with varying degrees of scoliosis from none to severe. Twenty-one patients initially received lower doses of risdiplam for at least 12 weeks. Of the patients treated with risdiplam for at least one year (n=30), the median change from baseline in Motor Function Measure (MFM), the primary endpoint in the confirmatory part of SUNFISH and a scale used to assess motor function in neuromuscular diseases, was a 3.1 point improvement. Sixty-three percent of patients experienced an improvement in MFM over baseline of three points or more after one year. Such improvements were seen both in patients under 12 years old (76%; n=17) and above 12 years old (46%; n=13). When considering patients who experienced any amount of improvement over baseline, the percentages were 70% overall, 76% for the younger age group, and 62% for the older patients. Serious adverse events that occurred in two or more of the 51 patients exposed to risdiplam were nausea (4%), upper respiratory tract infection (4%), and vomiting (4%). To date there have been no drug-related safety findings leading to withdrawal from any study.

Follow up is ongoing for the confirmatory Part 2 portions of both the FIREFISH and SUNFISH studies.

This site uses cookies and analysis tools to improve the usability of the site. More information. |